Matches in Nanopublications for { ?s ?p "[The molecular pathogenesis of resistance against tyrosine kinase inhibitors imatinib, nilotinib, or dasatinib in patients treated for chronic myeloid leukemia is best understood based on mutations within the ABL-kinase domain.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }
Showing items 1 to 4 of
4
with 100 items per page.
- assertion description "[The molecular pathogenesis of resistance against tyrosine kinase inhibitors imatinib, nilotinib, or dasatinib in patients treated for chronic myeloid leukemia is best understood based on mutations within the ABL-kinase domain.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- NP786895.RA2VeoIMD6Dy5BMGq5FUgAcsKOi6Te16om_G1notP8IXM130_assertion description "[The molecular pathogenesis of resistance against tyrosine kinase inhibitors imatinib, nilotinib, or dasatinib in patients treated for chronic myeloid leukemia is best understood based on mutations within the ABL-kinase domain.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP786895.RA2VeoIMD6Dy5BMGq5FUgAcsKOi6Te16om_G1notP8IXM130_provenance.
- NP786896.RAX36JgQ830otbOM69JgsaUJ9fXf73SCixL3oIlDZP-1g130_assertion description "[The molecular pathogenesis of resistance against tyrosine kinase inhibitors imatinib, nilotinib, or dasatinib in patients treated for chronic myeloid leukemia is best understood based on mutations within the ABL-kinase domain.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP786896.RAX36JgQ830otbOM69JgsaUJ9fXf73SCixL3oIlDZP-1g130_provenance.
- assertion description "[The molecular pathogenesis of resistance against tyrosine kinase inhibitors imatinib, nilotinib, or dasatinib in patients treated for chronic myeloid leukemia is best understood based on mutations within the ABL-kinase domain.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.